Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312781 | 0.92 | PRMT6 (0.44) | PRMT6P2RY12PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL12851855 | 0.81 | PRMT6 (0.46) | PRMT6P2RY12PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL12851647 | 0.81 | PRMT6 (0.46) | PRMT6P2RY12PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL12386688 | 0.80 | PRMT6 (0.51) | PRMT6P2RY12PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL15195613 | 0.79 | AHCY (0.38) | ADORA1 | |
| SCHEMBL17446884 | 0.79 | PRMT6 (0.47) | PRMT6P2RY12PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16648569 | 0.79 | PRMT6 (0.42) | PRMT6P2RY12PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16661549 | 0.79 | PRMT6 (0.42) | PRMT6P2RY12PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL12429685 | 0.79 | AHCY (0.44) | ADORA1 | |
| SCHEMBL17000751 | 0.79 | PRMT6 (0.48) | PRMT6P2RY12PRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513214-B2 | C4′-substituted-2-deoxyadenosine analogs and methods of treating HIV | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110190226-A1 | C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV | THE GOV. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2011-08-04 | — | — | US | disclosed |
| WO-2009064387-A2 | C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV | GOV'T OF THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190226-A1 | C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV | ADORA3, ADA, ADAR | PRMT6 2164/4885P2RY12 266/4885PRKAB2 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.